Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they ...

Abbott Diabetes Care was created in 2004 with the ... where he led the global pharmaceutical business, including commercial operations, research and development and manufacturing.

A CGM helps me run marathons and do epic bike rides better than ever.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Stay connected with Abbott for news, educational resources and innovations in the field of diagnostics.

Health care systems are making big investments in AI, and these companies are on the bleeding edge of that transition.

The CardioMEMS HF system. [Image courtesy of Abbott] An Abbott (NYSE: ABT) + official said on social media that the company secured a significant Medicare win for its CardioMEMS platform.